Investment Director, Roche Venture Fund
Mitchell Mutz, PhD, is Investment Director at the Roche Venture Fund. He joined Roche in 2017, bringing a broad depth of experience as founder, President, and Chief Scientific Officer of Amplyx Pharmaceuticals, a clinical stage therapeutics company that is currently developing APX001, a novel, broad spectrum antifungal compound. Amplyx has attracted over $130M in venture and grant financing. At Amplyx, he identified, led negotiations, and successfully in-licensed APX001. Mitchell also authored or co-authored 13 funded NIH grant proposals, garnering over $11M in non-dilutive funding. He is also an inventor on 32 issued patents.
Previously, Mitchell was the first employee and Principal Scientist at Labcyte Inc., Sunnyvale, CA, a tools company that uses acoustic beams to achieve precise, non-contact transfer of liquid without the use of pipet tips. Labcyte has received widespread industry recognition including selection by the World Economic Forum as a 2015 Technology Pioneer, has over 220 employees worldwide, and has seen their technology adopted by all top ten large pharmaceutical companies and a host of smaller biotechnology companies, universities, and research institutes. Prior to Labcyte, he was a research scientist at Scios which was later acquired by Johnson and Johnson. Mitchell currently serves on the board of Purigen Biosytems, is a board observer for Biodesy and Fabric Genomics, and was previously on the board of Amplyx.
Dr. Mutz received his PhD in Chemistry from the University of Rochester, NY, his Diploma in Orchestral Studies from the University of London, England, and a BA in Chemistry from Oberlin College.